NetMoint is developed, a multimodal framework integrating partially observed plasma proteomic, structural magnetic resonance imaging and cerebral haemodynamic phenotypes to predict individualized risks of Alzheimer's disease, vascular dementia and frontotemporal dementia across 1, 5, 10- and 20-year horizons, establishing a multimodal framework for trajectory-resolved dementia risk stratification.
Abstract
Dementia comprises biologically heterogeneous disorders, yet current risk assessment provides limited insight into how subtype-specific risk emerges and diverges before clinical diagnosis. We developed NetMoint, a multimodal framework integrating partially observed plasma proteomic, structural magnetic resonance imaging and cerebral haemodynamic phenotypes to predict individualized risks of Alzheimer's disease (AD), vascular dementia (VD) and frontotemporal dementia (FTD) across 1-, 5-, 10- and 20-year horizons. Among 104,120 UK Biobank participants free of dementia at baseline, NetMoint achieved mean area under the receiver operating characteristic curve (AUC) values of 0.937, 0.930 and 0.932 for AD, VD and FTD, respectively. The biological determinants of prediction shifted with time, from structural brain vulnerability at shorter horizons towards circulating molecular signatures at longer horizons, with distinct subtype-specific biological profiles. Multi-horizon risk profiling identified distinct temporal trajectories of dementia susceptibility. Among participants who subsequently developed AD, 0.7% followed a persistently very-high-risk trajectory, with predicted risk reaching 53.50% at 20 years, whereas 8.3% of those who developed FTD followed an increasing very-high-risk trajectory, reaching 67.17%. These high-risk trajectories were marked by distinct molecular signatures, with lower TGFB1 characterizing the AD group and higher NDRG1 the FTD group. In an independent ADNI-to-UK Biobank analysis, AD risk prediction remained informative after harmonization to 138 shared features, with an AUC of 0.741 at 20 years. Together, these findings establish a multimodal framework for trajectory-resolved dementia risk stratification, identifying small but high-risk populations within dementia subtypes and linking their divergent risk trajectories to distinct molecular signatures.
These findings, replicated in four diverse and independent datasets, support imaging-based subtyping as a scalable and clinically translatable approach for capturing heterogeneity in AD pathophysiology and associated cognitive trajectories.
A. Metz, Cassandra Polizzi, R. Moqadam et al.· medRxiv· 0 citations
The study reveals marked variability among individuals who are otherwise all defined as cognitively normal, and provides a data-driven stratification framework for enriching disease-modifying and preventive trials by identifying cognitively normal individuals at high risk for future cognitive decline.
An explainable multimodal machine-learning framework to predict progression from MCI to dementia within a clinically meaningful two-year period is developed and the convergence of cognitive impairment and region-specific neurodegeneration emerged as the strongest indicator of conversion risk.
Bipul Simkhada, T. Y. Liang, Xue-Ting Cui et al.· GeroScience· 1 citation· ⚡1
Bomarker-confirmed AD comprised internally reproducible atrophy trajectories with distinct cognitive, vascular, and molecular profiles and may complement fluid biomarkers and conventional volumetry for patient stratification and prognosis.
Chen-Hui Mao, Yu-Yue Qiu, Bo Li et al.· NeuroImage· 0 citations
Up to 45% of dementia can be prevented by addressing modifiable risk factors. Brain Health Services (BHS) are emerging across Europe, targeting individuals with subjective cognitive decline (SCD) to assess, communicate and reduce their risk of dementia. Our aim is to characterize our BHS cohort, and assess differences...
F. E. Pozzi, Francesca Solivani, I. Vitagliano et al.· Neurological Sciences· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.